Roche and IBM to Co-Develop, Commercialize IBM's DNA Transistor Technology for Nanopore Sequencing
July 06, 2010
Roche and IBM to Co-Develop, Commercialize IBM's DNA Transistor Technology for Nanopore Sequencing
Roche will fund development of the nanopore sequencer at IBM, and will receive an exclusive right to market products based on the technology. A device could be brought to market in five years, according to a Roche executive.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Nanopore Sequencing Makes Strides in 2010 as Technology Improves, Investment Grows
January 11, 2011 / In Sequence - For 454 Technology, Roche Bets on Specific Apps, Taking Share from Sanger
August 10, 2010 / In Sequence - Roche's Sequencing Sales Decline 15 Percent in Q1
April 20, 2010 / In Sequence - Roche Licenses Nanopore Readout Tech to Augment IBM's DNA Transistor Platform
October 11, 2011 / In Sequence - 454 Attributes Decline in Q2 Revenues to Delays from Customers Awaiting GS FLX+ Upgrade
July 26, 2011 / In Sequence